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1) Nivolumab plus Ipilimumab versus Sunitinib in 
Advanced Renal-Cell Carcinoma
Nivolumab plus ipilimumab produced objective responses 
in patients with advanced renal-cell carcinoma in a pilot study. 
This phase 3 trial compared nivolumab plus ipilimumab with 
sunitinib for previously untreated clear-cell advanced renal-
cell carcinoma
We randomly assigned adults in a 1:1 ratio to receive either 
nivolumab (3 mg per kilogram of body weight) plus ipilimumab 
(1 mg per kilogram) intravenously every 3 weeks for four doses, 
followed by nivolumab (3 mg per kilogram) every 2 weeks, 
or sunitinib (50 mg) orally once daily for 4 weeks (6-week 
cycle). The coprimary end points were overall survival (alpha 
level, 0.04), objective response rate (alpha level, 0.001), and 
progression-free survival (alpha level, 0.009) among patients 
with intermediate or poor prognostic risk.
A total of 1096 patients were assigned to receive nivolumab 
plus ipilimumab (550 patients) or sunitinib (546 patients); 425 
and 422, respectively, had intermediate or poor risk. At a median 
follow-up of 25.2 months in intermediate- and poor-risk patients, 
the 18-month overall survival rate was 75% (95% confidence 
interval [CI], 70 to 78) with nivolumab plus ipilimumab and 
60% (95% CI, 55 to 65) with sunitinib; the median overall 
survival was not reached with nivolumab plus ipilimumab 
versus 26.0 months with sunitinib (hazard ratio for death, 0.63; 
P<0.001). The objective response rate was 42% versus 27% 
(P<0.001), and the complete response rate was 9% versus 1%. 
The median progression-free survival was 11.6 months and 8.4 
months, respectively (hazard ratio for disease progression or 
death, 0.82; P=0.03, not significant per the prespecified 0.009 
threshold). Treatment-related adverse events occurred in 509 
of 547 patients (93%) in the nivolumab-plus-ipilimumab group 
and 521 of 535 patients (97%) in the sunitinib group; grade 3 
or 4 events occurred in 250 patients (46%) and 335 patients 
(63%), respectively. Treatment-related adverse events leading 
to discontinuation occurred in 22% and 12% of the patients 
in the respective groups. The recommended schedule and 
dose for this combination is nivolumab, 3 mg/kg, followed 
by ipilimumab, 1 mg/kg, on the same day every 3 weeks for 
4 doses, then nivolumab, 240 mg, every 2 weeks or 480 mg 
every 4 weeks. Overall survival and objective response rates 
were significantly higher with nivolumab plus ipilimumab than 
with sunitinib among intermediate- and poor-risk patients with 
previously untreated advanced renal-cell carcinoma. 
On 16 April 2018, the US Food and Drug Administration 
(FDA) granted approvals to nivolumab and ipilimumab (Op-
divo and Yervoy, Bristol-Myers Squibb Co.) in combination 
for the treatment of intermediate or poor risk, previously 
untreated advanced renal cell carcinoma (RCC).
2) Cabozantinib versus sunitinib as initial therapy  
for metastatic renal cell carcinoma of intermediate  
or poor risk (Alliance A031203 CABOSUN  
randomised trial): Progression-free survival by 
independent review and overall survival update
The randomised phase 2 CABOSUN trial comparing 
cabozantinib with sunitinib as initial therapy for advanced 
renal cell carcinoma (RCC) of intermediate or poor risk met 
the primary end-point of improving progression-free survival 
(PFS) as assessed by investigator. Previously untreated patients 
with advanced RCC of intermediate or poor risk by IMDC 
criteria were randomised 1:1 to cabozantinib 60 mg daily or 
sunitinib 50 mg daily (4 weeks on/2 weeks off). 
A total of 157 patients were randomised 1:1 to cabozantinib 
(n = 79) or sunitinib (n = 78). Median PFS per IRC was 8.6 
months (95% confidence interval [CI] 6.8-14.0) versus 5.3 
months (95% CI 3.0-8.2) for cabozantinib versus sunitinib 
(hazard ratio [HR] 0.48 [95% CI 0.31-0.74]; two-sided p 
= 0.0008), and ORR per IRC was 20% (95% CI 12.0-30.8) 
versus 9% (95% CI 3.7-17.6), respectively. Subgroup analyses 
of PFS by stratification factors and MET tumour expression 
were consistent with results for the overall population. With 
a median follow-up of 34.5 months, median OS was 26.6 
months (95% CI 14.6-not estimable) with cabozantinib and 
21.2 months (95% CI 16.3-27.4) with sunitinib (HR 0.80 [95% 
CI 0.53-1.21]. The incidence of grade 3 or 4 adverse events 
was 68% for cabozantinib and 65% for sunitinib.
In this phase 2 trial, cabozantinib treatment significantly 
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prolonged PFS per IRC compared with sunitinib as initial sys-
temic therapy for advanced RCC of poor or intermediate risk.
3) Survival with Durvalumab after  
Chemoradiotherapy in Stage III NSCLC
An earlier analysis in this phase 3 trial showed that dur-
valumab significantly prolonged progression-free survival, 
as compared with placebo, among patients with stage III, 
unresectable non-small-cell lung cancer (NSCLC) who did not 
have disease progression after concurrent chemoradiotherapy. 
Here we report the results for the second primary end point 
of overall survival.
We randomly assigned patients, in a 2:1 ratio, to receive 
durvalumab intravenously, at a dose of 10 mg per kilogram 
of body weight, or matching placebo every 2 weeks for up 
to 12 months. Randomization occurred 1 to 42 days after the 
patients had received chemoradiotherapy and was stratified 
according to age, sex, and smoking history. The primary end 
points were progression-free survival (as assessed by blinded 
independent central review) and overall survival. Secondary 
end points included the time to death or distant metastasis, 
the time to second progression, and safety.
Of the 713 patients who underwent randomization, 709 
received the assigned intervention (473 patients received 
durvalumab and 236 received placebo). As of March 22, 
2018, the median follow-up was 25.2 months. The 24-month 
overall survival rate was 66.3% (95% confidence interval 
[CI], 61.7 to 70.4) in the durvalumab group, as compared 
with 55.6% (95% CI, 48.9 to 61.8) in the placebo group 
(two-sided P=0.005). Durvalumab significantly prolonged 
overall survival, as compared with placebo (stratified hazard 
ratio for death, 0.68; 99.73% CI, 0.47 to 0.997; P=0.0025). 
Updated analyses regarding progression-free survival were 
similar to those previously reported, with a median duration 
of 17.2 months in the durvalumab group and 5.6 months in the 
placebo group (stratified hazard ratio for disease progression or 
death, 0.51; 95% CI, 0.41 to 0.63). The median time to death 
or distant metastasis was 28.3 months in the durvalumab group 
and 16.2 months in the placebo group (stratified hazard ratio, 
0.53; 95% CI, 0.41 to 0.68). A total of 30.5% of the patients 
in the durvalumab group and 26.1% of those in the placebo 
group had grade 3 or 4 adverse events of any cause; 15.4% 
and 9.8% of the patients, respectively, discontinued the trial 
regimen because of adverse events.
Durvalumab therapy resulted in significantly longer overall 
survival than placebo. No new safety signals were identified. 
4) Cancer Risks for PMS2-Associated  
Lynch Syndrome
Lynch syndrome due to pathogenic variants in the DNA 
mismatch repair genes MLH1, MSH2, and MSH6 is pre-
dominantly associated with colorectal and endometrial cancer, 
although extracolonic cancers have been described within the 
Lynch tumor spectrum. However, the age-specific cumulative 
risk (penetrance) of these cancers is still poorly defined for 
PMS2-associated Lynch syndrome. Using a large data set from 
a worldwide collaboration, our aim was to determine accurate 
penetrance measures of cancers for carriers of heterozygous 
pathogenic PMS2 variants. 
In total, 284 families consisting of 4,878 first- and second-
degree family members were included in the analysis. PMS2 
mutation carriers were at increased risk for colorectal cancer 
(cumulative risk to age 80 years of 13% [95% CI, 7.9% to 22%] 
for males and 12% [95% CI, 6.7% to 21%] for females) and 
endometrial cancer (13% [95% CI, 7.0%-24%]), compared with 
the general population (6.6%, 4.7%, and 2.4%, respectively). 
There was no clear evidence of an increased risk of ovarian, 
gastric, hepatobiliary, bladder, renal, brain, breast, prostate, 
or small bowel cancer.
Heterozygous PMS2 mutation carriers were at small in-
creased risk for colorectal and endometrial cancer but not for 
any other Lynch syndrome-associated cancer. This finding justi-
fies that PMS2-specific screening protocols could be restricted 
to colonoscopies. The role of risk-reducing hysterectomy and 
bilateral salpingo-oophorectomy for PMS2 mutation carriers 
needs further discussion.
5) First-Line Atezolizumab plus Chemotherapy  
in Extensive-Stage Small-Cell Lung Cancer
Enhancing tumor-specific T-cell immunity by inhibiting 
programmed death ligand 1 (PD-L1)-programmed death 
1 (PD-1) signaling has shown promise in the treatment of 
extensive-stage small-cell lung cancer. Combining checkpoint 
inhibition with cytotoxic chemotherapy may have a synergistic 
effect and improve efficacy.
We conducted this double-blind, placebo-controlled, 
phase 3 trial to evaluate atezolizumab plus carboplatin and 
etoposide in patients with extensive-stage small-cell lung 
cancer who had not previously received treatment. Patients 
were randomly assigned in a 1:1 ratio to receive carboplatin 
and etoposide with either atezolizumab or placebo for four 
21-day cycles (induction phase), followed by a maintenance 
phase during which they received either atezolizumab or 
placebo.The two primary end points were investigator-
assessed progression-free survival and overall survival in 
the intention-to-treat population.
A total of 201 patients randomly assigned to the atezoli-
zumab group, and 202 patients to the placebo group. were 
At ea mdian follow-up of 13.9 months, the median overall 
survival was 12.3 months in the atezolizumab group and 10.3 
months in the placebo group (hazard ratio for death, 0.70; 
95% confidence interval [CI], 0.54 to 0.91; P=0.007). The 
median progression-free survival was 5.2 months and 4.3 
months, respectively (hazard ratio for disease progression 
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or death, 0.77; 95% CI, 0.62 to 0.96; P=0.02). The safety 
profile of atezolizumab plus carboplatin and etoposide was 
consistent with the previously reported safety profile of the 
individual agents, with no new findings observed. The addition 
of atezolizumab to chemotherapy in the first-line treatment of 
extensive-stage small-cell lung cancer resulted in significantly 
longer overall survival and progression-free survival than 
chemotherapy alone.
6) Osimertinib versus standard-of-care EGFR-TKI as 
first-line treatment in patients with EGFRm advanced 
NSCLC: FLAURA Asian subset
FLAURA a multicentre, international, randomised, double-
blind, active-controlled trial conducted in 556 patients with 
EGFR exon 19 deletion or exon 21 L858R mutation-positive, 
unresectable or metastatic NSCLC who had not received 
previous systemic treatment for advanced disease. Patients 
were randomised (1:1) to receive osimertinib 80 mg orally 
once daily or standard-of-care (SoC) treatment of gefitinib 
250 mg or erlotinib 150 mg orally once daily. Of those ran-
domised to SoC, 20% received osimertinib as the next line of 
antineoplastic therapy.
The estimated median progression-free survival (PFS) was 
18.9 months (95% CI: 15.2, 21.4) in the osimertinib arm and 
10.2 months (95% CI: 9.6, 11.1) in the SoC arm (hazard ratio 
0.46 (95% CI: 0.37, 0.57), p <0.0001). The confirmed overall 
response rate was 77% for the osimertinib arm and 69% for 
the SoC arm. The estimated median response durations for 
the osimertinib and SoC arms were 17.6 and 9.6 months, 
respectively. At the time of the primary PFS analysis, there 
were too few deaths to estimate or compare overall survival.
The most common adverse reactions (occurring in at 
least 20% of patients treated with osimertinib) were diar-
rhoea, rash, dry skin, nail toxicity, stomatitis, and decreased 
appetite. Serious adverse reactions were reported in 4% of 
patients treated with osimertinib. The most common serious 
adverse reactions (≥1%) were pneumonia (2.9%), interstitial 
lung disease/pneumonitis (2.1%), and pulmonary embolism 
(1.8%). The recommended dose of osimertinib is 80 mg orally 
once daily, with or without food. 
On 18 April 2018, the US Food and Drug Administra-
tion (FDA) approved osimertinib (Tagrisso, AstraZeneca 
Pharmaceuticals LP) for the first-line treatment of patients 
with metastatic non-small cell lung cancer (NSCLC) whose 
tumours have epidermal growth factor receptor (EGFR) exon 
19 deletions or exon 21 L858R mutations, as detected by an 
FDA-approved test.
7) Dacomitinib versus gefitinib as first-line treatment 
for patients with EGFR-mutation-positive non-small-
cell lung cancer (ARCHER 1050): a randomised, open-
label, phase 3 trial
The FDA approved the kinase inhibitor dacomitinib (Vi-
zimpro, Pfizer) for the first-line treatment of patients with 
metastatic non-small cell lung cancer (NSCLC) with epidermal 
growth factor receptor (EGFR) exon 19 deletion or exon 21 
L858R substitution mutations as detected by an FDA-approved 
test. The approval was based on a randomized, multicenter, 
open-label, active-controlled trial (ARCHER 1050) comparing 
the safety and efficacy of dacomitinib with gefitinib (Iressa, 
AstraZeneca) in 452 patients with unresectable, metastatic 
NSCLC. Patients were required to have no prior therapy 
for metastatic disease or recurrent disease, with a 12-month 
minimum of disease-free status after completion of systemic 
non-EGFR tyrosine kinase inhibitor–containing therapy; an 
ECOG status of 0 or 1 and EGFR exon 19 deletion or exon 
21 L858R substitution mutations. 
Patients were randomly assigned (1:1) to receive either 45 
mg of dacomitinib orally once daily or 250 mg of gefitinib 
orally once daily until disease progression or unacceptable 
toxicity.The researchers were looking for a significant improve-
ment in progression-free survival (PFS), no improvement in 
overall response rate or overall survival. The median PFS, as 
determined by an independent review committee, was 14.7 and 
9.2 months in the dacomitinib and gefitinib arms, respectively 
(hazard ratio, 0.59; 95% CI, 0.47-0.74; P <0.0001).
Of 394 patients who received dacomitinib, serious adverse 
reactions occurred in 27%. The most common adverse reac-
tions resulting in discontinuation of dacomitinib were diarrhea 
and ILD. The most common adverse reactions of dacomitinib 
were diarrhea, rash, paronychia, stomatitis, decreased appetite, 
dry skin, decreased weight, alopecia, cough and pruritus. “The 
findings from ARCHER 1050 suggest that Vizimpro should 
be considered as a new first-line treatment option for patients 
with EGFR-mutated non-small cell lung cancer exon 19 dele-
tion or exon 21 L858R substitution mutations”.
